Search Results

EHop-016 5 mg  | 97.69%

TargetMol

EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-231 and MDA-MB-435 cells, equally effective inhibition for Rac3.

More Information Supplier Page

EHop-016 50 mg  | 97.69%

TargetMol

EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-231 and MDA-MB-435 cells, equally effective inhibition for Rac3.

More Information Supplier Page

EHop-016 25 mg  | 97.69%

TargetMol

EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-231 and MDA-MB-435 cells, equally effective inhibition for Rac3.

More Information Supplier Page

Dapagliflozin 5 mg  | 99.74%

TargetMol

Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

More Information Supplier Page

Dapagliflozin 50 mg  | 99.74%

TargetMol

Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

More Information Supplier Page

Dapagliflozin 10 mg  | 99.74%

TargetMol

Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

More Information Supplier Page

Dapagliflozin 100 mg  | 99.74%

TargetMol

Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

More Information Supplier Page

RGB-286638 free base 5 mg  | Purity Not Available

TargetMol

RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 and cyclin D3-CDK6.

More Information Supplier Page